

VÃ©ronique Minard-Colin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2536467/publications.pdf>

Version: 2024-02-01

84
papers

2,623
citations

218677

26
h-index

214800

47
g-index

85
all docs

85
docs citations

85
times ranked

3203
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc γ RI, Fc γ RIII, and Fc γ RIV. <i>Blood</i> , 2008, 112, 1205-1213.	1.4	214
2	Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. <i>Journal of Clinical Oncology</i> , 2015, 33, 2963-2974.	1.6	202
3	Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1566-1575.	10.7	161
4	Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. <i>New England Journal of Medicine</i> , 2020, 382, 2207-2219.	27.0	157
5	Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG) Tj ETQq1 1 0.784314 rgBT /Overfoc 19, 1061-1071.	10.7	137
6	Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. <i>Clinical Cancer Research</i> , 2017, 23, 6101-6112.	7.0	102
7	Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). <i>European Journal of Cancer</i> , 2020, 127, 123-129.	2.8	71
8	Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10507-10507.	1.6	62
9	Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intraoperative risk factors and the completeness of resection. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1543-1549.	1.5	61
10	Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Societe Francaise des Cancers de l'Enfant study. <i>Haematologica</i> , 2015, 100, 810-817.	3.5	58
11	Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma " A report from the Soci�t� Fran�saise des Cancers et leuc�mies de l'Enfant et de l'adolescent (SFCE). <i>European Journal of Cancer</i> , 2012, 48, 2409-2416.	2.8	57
12	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	2.8	52
13	Minimally invasive surgery of neuroblastic tumors in children: Indications depend on anatomical location and image-defined risk factors. <i>Pediatric Blood and Cancer</i> , 2015, 62, 257-261.	1.5	50
14	Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 352-359.	0.8	47
15	Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26902.	1.5	44
16	The EpSSG NRSTS 2005 treatment protocol for desmoid-type fibromatosis in children: an international prospective case series. <i>The Lancet Child and Adolescent Health</i> , 2017, 1, 284-292.	5.6	43
17	Localized vaginal/uterine rhabdomyosarcoma" results of a pooled analysis from four international cooperative groups. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27096.	1.5	40
18	ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. <i>European Journal of Cancer</i> , 2019, 110, 74-85.	2.8	39

#	ARTICLE	IF	CITATIONS
19	Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2979-2990.	1.6	38
20	SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2020, 44, 607-616.	3.7	37
21	Melanotic neuroectodermal tumor of infancy (MNTI) of the head and neck: A French multicenter study. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2018, 46, 201-206.	1.7	36
22	Roboticâ€assisted laparoscopic management of renal tumors in children: Preliminary results. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27867.	1.5	36
23	Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. <i>Blood</i> , 2016, 127, 1886-1895.	1.4	33
24	Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSÃ©-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. <i>European Journal of Cancer</i> , 2021, 150, 53-62.	2.8	33
25	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>European Journal of Cancer</i> , 2015, 51, 2386-2395.	2.8	32
26	Modeling the Interaction between the Microenvironment and Tumor Cells in Brain Tumors. <i>Neuron</i> , 2020, 108, 1025-1044.	8.1	31
27	Quality of life and functional outcome of male patients with bladderâ€prostate rhabdomyosarcoma treated with conservative surgery and brachytherapy during childhood. <i>Brachytherapy</i> , 2016, 15, 306-311.	0.5	30
28	Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. <i>Cell Death and Disease</i> , 2021, 12, 713.	6.3	29
29	Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. <i>European Journal of Cancer</i> , 2020, 137, 183-192.	2.8	28
30	Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee. <i>Cancer Medicine</i> , 2020, 9, 2698-2709.	2.8	28
31	Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study. <i>Cancer</i> , 2018, 124, 1016-1024.	4.1	25
32	Outcome of relapse in children and adolescents with Bâ€cell nonâ€Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27873.	1.5	25
33	Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer. <i>European Journal of Cancer</i> , 2022, 160, 112-133.	2.8	24
34	Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations. <i>Cancers</i> , 2021, 13, 2075.	3.7	23
35	Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).. <i>Journal of Clinical Oncology</i> , 2018, 36, LBA2-LBA2.	1.6	23
36	Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience. <i>Cancer Medicine</i> , 2018, 7, 1384-1393.	2.8	22

#	ARTICLE	IF	CITATIONS
37	Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 3730-3740.	1.6	22
38	Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2018, 36, 3466-3476.	1.6	21
39	Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. <i>Cancer</i> , 2020, 126, 823-831.	4.1	21
40	Non-parameningeal head and neck rhabdomyosarcoma in children, adolescents, and young adults: Experience of the European paediatric Soft tissue sarcoma Study Group (EpSSG) "RMS2005 study. <i>European Journal of Cancer</i> , 2021, 151, 84-93.	2.8	21
41	Pulsed-dose rate brachytherapy for pediatric bladder prostate rhabdomyosarcoma: Compliance and early clinical results. <i>Radiotherapy and Oncology</i> , 2017, 124, 285-290.	0.6	20
42	Nonparameningeal head and neck rhabdomyosarcoma in children and adolescents: Lessons from the consecutive International Society of Pediatric Oncology Malignant Mesenchymal Tumor studies. <i>Head and Neck</i> , 2017, 39, 24-31.	2.0	20
43	Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience. <i>European Journal of Cancer</i> , 2021, 146, 21-29.	2.8	20
44	Late toxicity of brachytherapy after female genital tract tumors treated during childhood: Prospective evaluation with a long-term follow-up. <i>Radiotherapy and Oncology</i> , 2015, 117, 206-212.	0.6	19
45	Rhabdomyosarcoma associated with germline TP53 alteration in children and adolescents: The French experience. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28486.	1.5	19
46	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. <i>European Journal of Cancer</i> , 2022, 172, 367-386.	2.8	19
47	Outcomes of metastatic non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) treated within the BERNIE study: a randomised, phase II study evaluating the addition of bevacizumab to chemotherapy. <i>European Journal of Cancer</i> , 2020, 130, 72-80.	2.8	18
48	Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3716-3724.	1.6	18
49	Robotic Surgery in Pediatric Oncology: Lessons Learned from the First 100 Tumors "A Nationwide Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 1315-1326.	1.5	17
50	Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG "RMS2005 study. <i>Cancer Medicine</i> , 2020, 9, 7580-7589.	2.8	16
51	Urachal rhabdomyosarcoma in childhood: a rare entity with a poor outcome. <i>Journal of Pediatric Surgery</i> , 2015, 50, 1329-1333.	1.6	14
52	Testicular transposition in children undergoing brachytherapy for bladder and/or prostate rhabdomyosarcoma. <i>Journal of Pediatric Surgery</i> , 2018, 53, 1428-1431.	1.6	13
53	Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28832.	1.5	13
54	Clinical, pathologic, and molecular features of inflammatory myofibroblastic tumors in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29460.	1.5	13

#	ARTICLE	IF	CITATIONS
55	Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease. <i>American Journal of Surgical Pathology</i> , 2021, 45, 854-867.	3.7	12
56	Outcome of localized liver–bile duct rhabdomyosarcoma according to local therapy: A report from the European Paediatric Soft–Tissue Sarcoma Study Group (EpSSG)–RMS 2005 study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27725.	1.5	11
57	Head and neck tumors in children and adolescents: Impact of a multidisciplinary tumor board. <i>Oral Oncology</i> , 2021, 114, 105145.	1.5	11
58	Primary post–transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients. <i>British Journal of Haematology</i> , 2021, 193, 1178-1184.	2.5	11
59	Brachytherapy for Pediatric Patients at Gustave Roussy Cancer Campus: A Model of International Cooperation for Highly Specialized Treatments. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 602-613.	0.8	11
60	Desmoid-type fibromatosis of the head and neck in children: A changing situation. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2019, 123, 33-37.	1.0	10
61	Intra–and extra–cranial <sc><i>BCOR</i></sc> ITD</sc> tumours are separate entities within the <sc><i>BCOR</i></sc>–rearranged family. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 217-232.	3.0	10
62	CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy. <i>Cancers</i> , 2021, 13, 5487.	3.7	9
63	Localised rhabdomyosarcoma in infants (<12 months) and young children (12–36 months of age) treated on the EpSSG RMS 2005 study. <i>European Journal of Cancer</i> , 2022, 160, 206-214.	2.8	8
64	Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study. <i>Haematologica</i> , 2022, 107, 2173-2182.	3.5	8
65	Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non–Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 1111-1124.	2.5	7
66	Analysis of Radiation Dose/Volume Effect Relationship for Anorectal Morbidity in Children Treated for Pelvic Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 231-241.	0.8	7
67	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. <i>Bulletin Du Cancer</i> , 2021, 108, 163-176.	1.6	7
68	Should treatment of ALK–positive anaplastic large cell lymphoma be stratified according to minimal residual disease?. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28982.	1.5	6
69	Long–term urological complications after conservative local treatment (surgery and brachytherapy) in children with bladder–prostate rhabdomyosarcoma: A single–team experience. <i>Pediatric Blood and Cancer</i> , 0, , e29532.	1.5	5
70	Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement. <i>Haematologica</i> , 2022, 107, 2255-2260.	3.5	5
71	Les anticorps monoclonaux dirig–s contre les checkpoints immunologiques: de nouvelles approches d–immunoth–rapie en onco-h–matologie. <i>Revue D'Oncologie H&#x2013;matologie P&#x2013;diatrique</i> , 2016, 4, 5-12. ^{0,1}		4
72	Perianal/perineal rhabdomyosarcoma: Results of the SIOP MMT 95, Italian RMS 96, and EpSSG RMS 2005 studies. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29739.	1.5	4

#	ARTICLE	IF	CITATIONS
73	Implementation of Image-Guided Brachytherapy for Pediatric Vaginal Cancers: Feasibility and Early Clinical Results. <i>Cancers</i> , 2022, 14, 3247.	3.7	4
74	Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group. <i>European Journal of Cancer</i> , 2022, 172, 119-129.	2.8	4
75	Congenital rhabdomyosarcoma: A report from the European paediatric Soft tissue sarcoma Study Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29376.	1.5	3
76	In childhood mature B-NHL with CNS disease, patients with blasts in cerebrospinal fluid are at higher risk of failure. <i>Blood Advances</i> , 2020, 4, 3621-3625.	5.2	2
77	PAX3&NCOA1 alveolar rhabdomyosarcoma of the tongue: A rare entity with challenging diagnosis and management. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29288.	1.5	2
78	Locally aggressive rarely metastazing tumors and low-grade sarcoma in children, adolescents and young adults: The benefits of a national network. <i>European Journal of Surgical Oncology</i> , 2021, , .	1.0	2
79	Locoregional Control and Survival in Children, Adolescents, and Young Adults With Localized Head and Neck Alveolar Rhabdomyosarcoma&NThe French Experience. <i>Frontiers in Pediatrics</i> , 2021, 9, 783754.	1.9	2
80	Pattern of relapse in pediatric localized extremity rhabdomyosarcomas correlated with locoregional therapies administered. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 690-699.	2.0	1
81	Reply to H. B et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102612.	1.6	1
82	ASO Visual Abstract: Robotic Surgery in Pediatric Oncology&NLessons Learned from the First 100 Tumors: A Nationwide Experience. <i>Annals of Surgical Oncology</i> , 2021, 28, 730-731.	1.5	0
83	A Mendelian Predisposition to B Cell Lymphoma Caused by IL-10R2 Deficiency. <i>Blood</i> , 2012, 120, 5092-5092.	1.4	0
84	Reply to R. Lakhotia et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102912.	1.6	0